Patient-derived tumour xenografts for breast cancer drug discovery

We describe the importance of extensive multidimensional molecular and functional characterisation of models and combination drug–drug screens to identify complex biomarkers of drug resistance and response. We reflect on our own experiences and propose the use of a cost-effective intermediate pharmacogenomic platform (the PDTX-PDTC platform) for breast cancer drug and biomarker discovery. We discuss the limitations and unanswered questions of PDTX models; yet, still strongly envision that their use in basic and translational research will dramatically change our understanding of breast cancer biology and how to more effectively treat it.

Source: Endocrine-Related Cancer - November 10, 2016 Category: Endocrinology Authors: Cassidy, J. W., Batra, A. S., Greenwood, W., Bruna, A. Tags: Thematic Review Source Type: research